Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV)
CUSIP: 004890109
Q3 2025 13F Holders as of 30 Sep 2025
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 42,655,924
- Total 13F shares
- 17,461,169
- Share change
- -341,661
- Total reported value
- $31,603,874
- Price per share
- $1.81
- Number of holders
- 45
- Value change
- -$171,329
- Number of buys
- 14
- Number of sells
- 30
Quarterly Holders Quick Answers
What is CUSIP 004890109?
CUSIP 004890109 identifies ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 004890109:
Top shareholders of ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Kristina Masson |
3/4/5
|
EVP - Business Operations, Director |
—
class O/S missing
|
2,819,375
|
$19,792,013 | — | 14 Aug 2024 | |
| Chione Ltd |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
3,848,632
|
$16,741,549 | — | 26 Jun 2023 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
20%
|
8,340,508
|
$9,925,205 | — | 30 Jun 2025 | |
| PERCEPTIVE ADVISORS LLC |
3/4/5
|
10%+ Owner |
7.3%
|
3,104,139
|
$4,159,546 | — | 30 Apr 2025 | |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
888,130
|
$3,863,366 | — | 17 Nov 2022 | |
| Sands Capital Alternatives, LLC |
13F
|
Company |
5%
|
2,122,605
|
$2,525,900 | — | 30 Jun 2025 | |
| Sands Capital Life Sciences Pulse Fund II, L.P. |
13D/G
|
— |
6.8%
|
2,122,605
|
$2,525,900 | $0 | 30 Jun 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
4.4%
|
1,895,519
|
$2,255,668 | — | 30 Jun 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
2.1%
|
888,130
|
$1,056,875 | — | 30 Jun 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
1.4%
|
593,247
|
$705,964 | — | 30 Jun 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
1.2%
|
509,295
|
$606,061 | — | 30 Jun 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0.96%
|
407,622
|
$485,071 | — | 30 Jun 2025 | |
| ACORN CAPITAL ADVISORS, LLC |
13F
|
Company |
0.95%
|
405,237
|
$482,232 | — | 30 Jun 2025 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
0.9%
|
382,234
|
$454,858 | — | 30 Jun 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.73%
|
311,829
|
$371,076 | — | 30 Jun 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.69%
|
296,239
|
$352,524 | — | 30 Jun 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.42%
|
181,187
|
$215,612 | — | 30 Jun 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.42%
|
181,172
|
$215,595 | — | 30 Jun 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.39%
|
164,362
|
$195,674 | — | 30 Jun 2025 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.36%
|
152,605
|
$181,600 | — | 30 Jun 2025 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.34%
|
145,895
|
$173,000 | — | 30 Jun 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.33%
|
140,055
|
$166,665 | — | 30 Jun 2025 | |
| Rasmus Holm-Jorgensen |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
135,397
mixed-class rows
|
$141,397 | — | 01 Mar 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.25%
|
106,119
|
$126,282 | — | 30 Jun 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.16%
|
67,145
|
$79,903 | — | 30 Jun 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.15%
|
63,636
|
$75,727 | — | 30 Jun 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.15%
|
63,016
|
$74,989 | — | 30 Jun 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.11%
|
46,776
|
$55,663 | — | 30 Jun 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.1%
|
43,860
|
$52,193 | — | 30 Jun 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.08%
|
32,600
|
$38,794 | — | 30 Jun 2025 | |
| CITIGROUP INC |
13F
|
Company |
0.08%
|
32,382
|
$38,535 | — | 30 Jun 2025 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.05%
|
22,900
|
$27,251 | — | 30 Jun 2025 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
0.05%
|
22,809
|
$27,143 | — | 30 Jun 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.05%
|
22,252
|
$26,480 | — | 30 Jun 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.05%
|
22,204
|
$26,439 | — | 30 Jun 2025 | |
| Quadrature Capital Ltd |
13F
|
Company |
0.05%
|
22,175
|
$26,277 | — | 30 Jun 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.05%
|
20,925
|
$24,901 | — | 30 Jun 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.05%
|
20,617
|
$24,534 | — | 30 Jun 2025 | |
| SG Americas Securities, LLC |
13F
|
Company |
0.04%
|
15,265
|
$18,000 | — | 30 Jun 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.03%
|
12,692
|
$15,103 | — | 30 Jun 2025 | |
| Ground Swell Capital, LLC |
13F
|
Company |
0.03%
|
12,215
|
$14,536 | — | 30 Jun 2025 | |
| FMR LLC |
13F
|
Company |
0.02%
|
9,850
|
$11,722 | — | 30 Jun 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.02%
|
8,844
|
$10,524 | — | 30 Jun 2025 | |
| China Universal Asset Management Co., Ltd. |
13F
|
Company |
0.01%
|
6,298
|
$7,495 | — | 30 Jun 2025 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
0.01%
|
2,318
|
$2,758 | — | 30 Jun 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
1,418
|
$1,687 | — | 30 Jun 2025 | |
| Mirae Asset Global Investments Co., Ltd. |
13F
|
Company |
0%
|
1,211
|
$1,442 | — | 30 Jun 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0%
|
992
|
$1,180 | — | 30 Jun 2025 | |
| CWM, LLC |
13F
|
Company |
0%
|
790
|
$1,000 | — | 30 Jun 2025 | |
| GF FUND MANAGEMENT CO. LTD. |
13F
|
Company |
0%
|
772
|
$919 | — | 30 Jun 2025 |
Institutional Holders of Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV) as of Q3 2025
As of 30 Sep 2025,
Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV) was held by
45 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
17,461,169 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., Sands Capital Alternatives, LLC, CITADEL ADVISORS LLC, WELLINGTON MANAGEMENT GROUP LLP, UBS Group AG, VANGUARD GROUP INC, RENAISSANCE TECHNOLOGIES LLC, ACORN CAPITAL ADVISORS, LLC, BlackRock, Inc., and TWO SIGMA INVESTMENTS, LP.
This page lists
46
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
52
Q3 2025 holders
45
Holder diff
-7
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 Value $ | Q3 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.